Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer

Model scores of the 29,894 trials active now.

Model score 27% for any early termination, 8% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2020-07-12. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cancermelanomastagecellsradiation
  Phrases that lowered it: participantsdexamethasonejointefficacydrug drug
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Drug's FAERS reports with a death: 29.9% (raises risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 121 (lowers risk) · Sponsor's track record
• Disease area, dermatology: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor's past trials: 395 (lowers risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Number of arms: 1 (raises risk) · Design
• Blinding: none (raises risk) · Design
• Collaborators: 1 (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Disease area, respiratory: Yes (raises risk) · Disease area
• Sponsor's past termination rate: 7.3% (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 86.0% (lowers risk) · Drug's FDA history
• Drug's FAERS reports before start: 24042 (raises risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 13659 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Phase II Trial of Nelfinavir With Concurrent Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck NCT02207439 · started 2014 · scored riskier than 99% of active trials completed
• Stereotactic Body Radiation With Nelfinavir for Oligometastases NCT01728779 · started 2014 · scored riskier than 99% of active trials completed
• Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma NCT03077451 · started 2017 · scored riskier than 53% of active trials completed
• A Trial of the Protease Inhibitor Nelfinavir and Concurrent Radiation and Temozolomide in Patients With WHO Grade IV Glioma NCT01020292 · started 2009 · scored riskier than 76% of active trials completed
• Study to Evaluate RAD001 in Combination With Radiotherapy in Non-small Cell Lung Cancer NCT01167530 · started 2008 · scored riskier than 87% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.